PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1494809
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1494809
According to Stratistics MRC, the Global Cardiovascular & Soft Tissue Repair Patch Market is accounted for $5.0 billion in 2024 and is expected to reach $9.0 billion by 2030 growing at a CAGR of 10.1% during the forecast period. Cardiovascular and Soft Tissue Repair Patches are medical devices used in surgical procedures to repair damaged or weakened tissues in the cardiovascular system or soft tissues elsewhere in the body. These patches are typically made from biocompatible materials, such as synthetic polymers or biological tissues, that are compatible with the body's natural healing processes. In cardiovascular surgeries, these patches are commonly used to repair defects in the heart's walls, such as septal defects or congenital heart defects, or to reinforce weakened areas of blood vessels, such as aneurysms or arteriotomies.
According to the article published by PubMed Central in August 2021, a cross-sectional study was performed on 500 participants in Saudi Arabia, which showed that the prevalence of abdominal hernia was 38.8 percent and the participants in 18-25 years had less prevalence of 21.2 percent.
Rising prevalence of cardiovascular disease and soft tissue injuries
Cardiovascular diseases, including heart attacks and congenital heart defects, becoming increasingly common due to factors like aging populations, lifestyle changes, and genetic predispositions, there is a growing demand for effective surgical interventions. Similarly, the incidence of soft tissue injuries, such as hernias and abdominal wall defects, is on the rise due to factors like increased physical activity and trauma. This surge in medical conditions requiring surgical repair boosts the demand for advanced repair patches. These patches offer reliable solutions for reinforcing or replacing damaged tissues, enhancing surgical outcomes and patient recovery driving the markets growth.
High cost of procedures
Advanced medical devices often come with substantial costs due to the sophisticated materials and technologies involved in their development and manufacturing. Consequently, the overall expense of surgical procedures using these patches can be prohibitive for many patients, particularly those without adequate health insurance coverage or in regions with limited healthcare funding. Therefore, the financial challenges associated with these procedures hinder the widespread adoption and growth of the cardiovascular and soft tissue repair patch market.
Advancements in material science and technology
Innovations in biocompatible materials, such as bioengineered tissues, synthetic polymers, and nanomaterials, have led to the development of more effective, durable, and versatile repair patches. These cutting-edge materials improve the patches' ability to integrate with natural tissues, reduce the risk of rejection, and enhance the overall healing process. In addition technological advancements have also enabled the creation of patches with specialized features, such as drug-eluting properties, which can deliver medications directly to the repair site to prevent infection and promote healing leading to increased adoption and expanded use of cardiovascular and soft tissue repair patches.
Stringent regulatory requirements
Regulatory agencies, such as the FDA and EMA, impose rigorous standards for safety, efficacy, and quality, requiring extensive clinical testing and documentation. This leads to prolonged development timelines and increased costs for manufacturers, who must invest significant resources to meet these stringent criteria. As a result, stringent regulatory requirements can limit the availability of new and improved cardiovascular and soft tissue repair patches, hindering market growth and delaying patient access to cutting-edge treatments.
Covid-19 Impact
Initially, lockdowns and resource allocation towards COVID-19 cases led to a decline in elective surgeries, including those requiring repair patches. This caused a temporary dip in market growth. However, as healthcare systems adapted, procedures resumed, and the market recovered. The focus on hygiene might have also driven aseptic patch adoption. Overall, after a temporary setback, the market is expected to return to its pre-pandemic growth trajectory, fueled by the rising prevalence of cardiovascular diseases and advancements in patch technology.
The cardiac patches segment is expected to be the largest during the forecast period
The cardiac patches is expected to be the largest during the forecast period as cardiac patches are often used in minimally invasive heart surgeries. This minimally invasive approach is a major trend in cardiovascular treatments, and cardiac patches play a key role in facilitating it. As minimally invasive procedures become more prevalent, the demand for cardiac patches is expected to rise. Moreover, effective cardiac patches can promote tissue regeneration, improve heart function, and reduce complications. This translates to better patient outcomes, leading to a higher adoption rate by surgeons and increased demand for these patches.
The vascular repair & reconstruction segment is expected to have the highest CAGR during the forecast period
The vascular repair & reconstruction segment is expected to have the highest CAGR during the forecast period because these procedures necessitate strong, durable, and biocompatible patches that can withstand the pressure of blood flow. This drives innovation in patch materials, with a focus on functionalities specifically suited for vascular applications. Further it also encompasses various procedures, from treating aneurysms to peripheral artery disease. The need for different patch types based on the specific application creates a diversified market for various patch technologies.
North America is projected to hold the largest market share during the forecast period due to the rising prevalence of cardiac diseases, the presence of a large number of pharmaceutical companies, growing research and development expenditure, and increasing incidences of hernia disorders. For instance, according to data from the Centers for Disease Control and Prevention in July 2022, heart disease is one of the leading causes of death in the United States. Among all the heart diseases coronary heart disease is the most common type of heart disease and about 20.1 million adults age 20 and older have coronary heart disease in the United States drives the growth of the market in this region.
Asia Pacific is projected to hold the highest CAGR over the forecast period owing to rapid developments in healthcare infrastructure, growing trends of minimally invasive surgical procedures, rising incidence of cardiac disease, increasing medical tourism, rapid economic expansion in several countries such as China and India, rising geriatric population, and increasing burden of chronic disorders, Asia Pacific is expected to register the fastest growing rate in the coming years. Additionally raising awareness about the importance of early diagnosis and detection of congenital cardiac disorders, as well as quick treatment propels the market.
Key players in the market
Some of the key players in Cardiovascular & Soft Tissue Repair Patch market include Abbott, Admedus, Atriummed, B.Braun, Bard Peripheral Vascular Inc., Baxter, CorMatrix, Cryolife, Inc., Edwards Life Sciences Corporation, Glycar SA Pty Ltd., Integra LifeSciences Corporation, LabCor, LeMaitre Vascular Inc., Maverick Bioscience, Neovasc, Novomedics, Southern Lights Biomaterials, TEI Biosciences Inc., Terumo Medical Corporation and W.L. Gore & Associates, Inc.
In April 2024, Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit(TM) BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK).
In April 2024, Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive. The Vantive mission, Extending Lives, Expanding Possibilities, will guide and inspire the proposed company, which will focus on vital organ therapies for acute and chronic kidney diseases and beyond.
In March 2024, Abbott, and the Real Madrid Foundation announced the extension of their partnership through Real Madrid's 2026-27 season. Abbott will remain Global Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.